Sanofi has rushed to the defence of blockbuster basal insulin product Lantus in the US once again ... of 10 patents covering the drug as well as Lilly’s SoloStar pen injector device. The case looks ...

A less-expensive version of the world's top-selling insulin, Sanofi's Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over patents for ...

The court decisions affirmed the U.S. Patent and Trademark Appeal Board's prior rulings that found the challenged claims of Sanofi's Lantus SoloSTAR ... vial and prefilled pen presentations ...

The French drugmaker said Monday it settled a lawsuit over patents for Lantus SoloStar, its once-daily insulin in a pen-like injector. The settlement allows rivals Eli Lilly and Co. and German ...